Clasp Therapeutics

Executive Summary

Clasp Therapeutics is a preclinical biotechnology company pioneering a novel class of T-cell engagers, termed 'Clasp' molecules, which are bispecific antibodies designed to bind two distinct tumor-specific antigens, thereby enhancing selectivity for cancer cells while minimizing off-target toxicities. Founded in 2023 and headquartered in Cambridge, MA, the company has raised $150 million in funding to advance its platform, which aims to address the narrow therapeutic window of conventional T-cell redirecting therapies. By requiring dual antigen recognition, Clasp molecules are expected to improve safety profiles and expand the applicability of immuno-oncology treatments to solid tumors. The company is currently advancing its lead candidates toward investigational new drug (IND)-enabling studies, with a focus on high unmet need indications.

Upcoming Catalysts (preview)

• Q2 2027IND submission for lead program70% success
• Q3 2026Preclinical data presentation at major oncology conference (e.g., AACR)90% success
• Q4 2026Potential partnership or strategic collaboration50% success